A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF IPTACOPAN IN IDIOPATHIC IMMUNE COMPLEX-MEDIATED MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)

  Back
WCN23-0584
Chronic Kidney Disease, Hypertension, Diabetes and CVD
Other CKD
 
 
 
 
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF IPTACOPAN IN IDIOPATHIC IMMUNE COMPLEX-MEDIATED MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)
Veldandi, U.K.(1)*;Kavanagh, D.(2);Vivarelli, M.(3);Bomback, A.(4);Wang, Y.(5);Bogdanowicz, K.(6);Webb, N.(7);Meier, M.(7);Smith, R.J.H.(8);
ie: Azwin Z.1, Siti Y.1, John D.2
(1)Global Drug Development, Novartis Healthcare Pvt Ltd, Hyderabad, India;(2)National Renal Complement Therapeutics Centre, Newcastle Upon Tyne Hospitals- National Health Service Foundation Trust, Newcastle Upon Tyne, United Kingdom;(3)Division Of Nephrology And Dialysis- Department Of Pediatric Subspecialties, Bambino Gesù Children'S Hospital, Irccs- Rome, Italy;(4)Division Of Nephrology- Department Of Medicine, Columbia University College Of Physicians And Surgeons, New York- Ny, United States;(5)Global Drug Development, Novartis Pharmaceuticals, Sandy- Ut, United States;(6)Global Drug Development, Novartis Pharmaceuticals, London, United Kingdom;(7)Global Drug Development, Novartis Pharma Ag, Basel, Switzerland;(8)Molecular Otolaryngology And Renal Research Laboratories And The Departments Of Internal Medicine And Pediatrics Divisions Of Nephrology, Carver College Of Medicine- University Of Iowa, Iowa City- Ia, United States;
https://storage.unitedwebnetwork.com/files/1041/5041e7eb56bd39058cbe4d5d3eaad85c.pdf
 
if any